Successful implementation of a rural extracorporeal photopheresis program for the treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease in a rural hospital
- PMID: 25691106
- DOI: 10.1002/jca.21382
Successful implementation of a rural extracorporeal photopheresis program for the treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease in a rural hospital
Abstract
Objective: Extracorporeal photopheresis (ECP) is currently standard therapy for cutaneous T-cell lymphoma (CTCL) and Graft-versus-host disease (GVHD). Of the many challenges associated with outpatient ECP treatments, commuter travel to capable facilities can fragment and compromise the patient care. In 2008, our hospital implemented an ECP program providing patients to a treatment center over 120 minutes away. This study was undertaken to describe our experience with the establishment of a regional ECP program.
Methods: A retrospective review using a standardized template was performed of patients treated from May 2008 to 2012. The response to treatment was analyzed after a minimum of eight procedures. A partial response to treatment in individuals with CTCL, was more than 50% skin improvement, and GVHD, a reduction in steroid dose by 50%, liver function test improvement or documented improvement in skin findings.
Results: Of the 34 patients treated, 11 were for CTCL and 23 for GVHD. 95.8% of the 1,071 planned procedures were successfully. The average procedure time was 186 min for the UVAR-XTSTM and 93 min for the CELLEXTM. Patients travelled a median of 65.7 miles (range 4-133 miles). The median duration of therapy was 6 months (range 2-23) for CTCL and 5 months (range 1-27) for GVHD. A clinical benefit was observed in 7 of 11 (63.6%) patients with CTCL and in 15 of 23 (65.2%) with GVHD.
Conclusion: Our regional ECP program was a viable option in improving access to care for patients requiring treatment for CTCL and chronic GVHD.
Keywords: ECP; cutaneous T-cell lymphoma; extracorporeal photopheresis; graft-versus-host disease; implementation.
© 2015 Wiley Periodicals, Inc.
Similar articles
-
Extracorporeal photophoresis: an evidence-based analysis.Ont Health Technol Assess Ser. 2006;6(6):1-82. Epub 2006 Mar 1. Ont Health Technol Assess Ser. 2006. PMID: 23074497 Free PMC article.
-
Reciprocal modulation of circulating CD4+CD25+bright T cells induced by extracorporeal photochemotherapy in cutaneous T-cell lymphoma and chronic graft-versus-host-disease patients.Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):353-62. doi: 10.1177/039463200902200212. Int J Immunopathol Pharmacol. 2009. PMID: 19505389
-
Extracorporeal photopheresis: what is it and when should it be used?Clin Exp Dermatol. 2009 Oct;34(7):757-60. doi: 10.1111/j.1365-2230.2009.03475.x. Epub 2009 Jul 29. Clin Exp Dermatol. 2009. PMID: 19663836 Review.
-
U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease.Br J Dermatol. 2008 Apr;158(4):659-78. doi: 10.1111/j.1365-2133.2007.08415.x. Epub 2008 Jan 30. Br J Dermatol. 2008. PMID: 18241274
-
Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group.Br J Dermatol. 2006 Jan;154(1):7-20. doi: 10.1111/j.1365-2133.2005.06857.x. Br J Dermatol. 2006. PMID: 16403088
Cited by
-
The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society.Br J Haematol. 2017 Apr;177(2):287-310. doi: 10.1111/bjh.14537. Epub 2017 Feb 21. Br J Haematol. 2017. PMID: 28220931 Free PMC article.
-
Tumor-associated macrophages increase the proportion of cancer stem cells in lymphoma by secreting pleiotrophin.Am J Transl Res. 2019 Oct 15;11(10):6393-6402. eCollection 2019. Am J Transl Res. 2019. PMID: 31737191 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical